Company intelligence / Profile preview

PAN Therapeutics

Tübingen, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

PAN Therapeutics is a German biotechnology company specializing in the development of next-generation RNA-based therapies for oncology. The company utilizes a proprietary RNA interference (RNAi) platform to target "undruggable" oncogenic drivers, with a primary focus on the Y-box binding protein 1 (YB-1). Its lead candidate, PAN-101, is designed to inhibit YB-1, a master regulator of tumor progression and therapy resistance in various aggressive cancers. By leveraging advanced nanoparticle delivery systems, PAN Therapeutics aims to provide precision medicine solutions for patients with limited treatment options, including those with triple-negative breast cancer and glioblastoma.

Therapeutic areas: Oncology
Modalities: Small interfering RNARNA therapyNanoparticle
Industry: Biotech

Beyond the preview

Go deeper on PAN Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAN Therapeutics.

Explore the full profile